X-Energy jumped 12% on a $1 billion DOE cost-share increase and its first public-company earnings, while enCore Energy collapsed 17% after an extraction miss forced it to buy uranium above its own selling price.

The session's leadership sat at the reactor-and-fuel chokepoint. X-Energy rose +11.7% to $22.73 after reporting second-quarter results before Thursday's open — its first full quarter as a public company since April's IPO — alongside word that the Department of Energy will increase its Advanced Reactor Demonstration Program cost-share by up to $1 billion, lifting total federal support to roughly $2.1 billion across the Xe-100 reference design, the TX-1 fuel facility and the Dow Seadrift deployment. Revenue and grant income rose 154% year-on-year to $54.6 million, and the company disclosed binding long-term HALEU fuel agreements with Centrus and General Atomics. Read through this vertical's frame, that is the two hardest links in the chain de-risked at once: the Xe-100 needs both a funded reactor program and a secured supply of enriched TRISO fuel, and X-Energy just locked the federal cost-share on the first and the offtake on the second, sitting on $1.9 billion of cash with no debt.

The laggard exposed the front end of the same fuel cycle at its most punishing. enCore Energy fell −17.4% to $1.14 after its Q2 print showed in-situ uranium extraction collapsing to 131,274 pounds from 317,613 a year earlier. To honor 485,000 pounds of contracted deliveries, the company had to buy roughly 360,000 pounds on the spot market — pushing its weighted-average delivered cost to $75.54 per pound against a realized sales price of $70.10, selling uranium below what it paid to source it. Its own extraction cost climbed to $57.36 per pound, and the six-month net loss widened to about $0.19 a share. The structural read is the uranium-supply chokepoint punishing a producer that cannot hold output: contracted pounds turn from asset to liability the moment your wells underdeliver and you are forced to cover in a tight market.

The rest of the developer complex firmed in sympathy. NANO Nuclear rose +7.9% to $20.52 the day after its own Q3 report — KRONOS microreactor accepted into NRC review, the STS acquisition closed, roughly $580 million of quarter-end cash — while Centrus gained +3.7% to $191.82 at the domestic-enrichment choke, itself a direct beneficiary of the X-Energy HALEU offtake, with Oklo +2.9% to $46.45, NuScale +2.7% to $9.85 and Mirion +2.6% to $15.60 at the instrumentation layer. There was no single documented sector policy catalyst; the read is that X-Energy's billion-dollar federal boost lifted sentiment across the DOE-dependent fuel-and-reactor names that share its thesis. Against them the forgings-and-components layer eased — Curtiss-Wright −4.8% to $688.83 and the Japan Steel Works ADR −5.4% to $23.24 giving back after their own run — with Cameco −1.3% to $97.75 and BWX Technologies −1.3% to $170.35 drifting alongside.

The near-term calendar keeps the revenue-and-capacity test in focus. Solstice Advanced Materials reports Q2 on September 2, the first read on the Metropolis Works UF6 conversion ramp at the only operating US converter. The World Nuclear Symposium convenes in London September 9–11, the fuel-cycle forum where the HALEU and conversion-capacity narratives get priced, and the NRC's final Environmental Impact Statement for GLE's Paducah laser-enrichment facility is targeted for September 30. Further out, BWX Technologies prints Q3 on November 2. The watch item is unchanged and now sharper: whether X-Energy's DOE cost-share and signed fuel agreements convert into the actual Xe-100 construction milestones its valuation has begun to assume.